Presenters
Endocrinologist, Division of Endocrinology & Metabolism
Prof. Alice Yuk-Yan Cheng, MD
Course Details
Discussion on the updates on the ESC 2019 and ADA 2021 guidelines for type 2 diabetes patients with cardiovascular risk. Discussion on the updates on the clinical trials of empagliflozin including the recently published EMPEROR Trials as well as the upcoming trials for empagliflozin.
CPD Points: 0.5 Point
PRC Program No: PROG-2021-21355
Moving the Treatment Landscape Forward in the Cardio-Renal-Metabolic Management of T2D Course Outline
- To update on the latest available guidelines on the treatment of patients with type 2 diabetes ESC, ADA/EASD,KDIGO
- To provide updates on the mechanism of action of the latest available oral anti-diabetic drugs specifically on empagliflozin.
- To discuss on the connection of metabolic-cardio-renal mechanisms of oral anti-diabetic drugs and its impact to disease outcomes particularly in cardiovascular and renal disease.
- To further discuss on the future of empagliflozin and other clinical trials to look out for.